UPDATE 2- U.S. FDA panel recommends new safety information on AstraZeneca's Onglyza

April 14, 2015 5:11 PM

13 0

WASHINGTON, April 14 (Reuters) - AstraZeneca Plc's diabetes drug Onglyza has a broadly acceptable cardiovascular safety profile but its label should include new information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday.

The recommendation did not include any restrictions on prescribing the drug, sending AstraZeneca's shares up 3.26 percent to $71.10 in afternoon trading.

Read more

To category page